Exploration and discovery of treatment targets for primary biliary cholangitis based on plasma and cerebrospinal fluid proteomics: A multicenter mendelian randomization study
PLOS One · 2026
DOI: 10.1371/journal.pone.0340166 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS One, 2026. Verfasst von Jianxin Xi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, ChangChun, Jilin, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary, Proteomics. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Natural Science Foundation of Jilin Province, Financial Department of Jilin Province.
Abstract (Originalsprache)
Background
Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune cholestatic liver disease. Current first-line therapy, ursodeoxycholic acid (UDCA), yields suboptimal response rates, leaving many patients at risk of disease progression. Thus, novel therapeutic targets are urgently needed to slow PBC progression.
Methods
We performed two-sample Mendelian randomization (MR) to identify proteins causally associated with PBC risk, using protein quantitative trait loci (pQTL) as genetic instruments. The discovery stage utilized PBC genome-wide association study (GWAS) summary statistics from Cordell et al., followed by replication in independent GWAS datasets from the IEU Open GWAS project and the FinnGen consortium. pQTL data were drawn from large-scale plasma (N = 2,656) and cerebrospinal fluid (CSF; N = 184) proteomic studies. We also conducted sensitivity analyses, including Bayesian colocalization, reverse-causality testing, and phenotype scanning. Identified protein targets were further examined via protein–protein interaction (PPI) network analysis.
Results
Three proteins showed significant associations with PBC risk after Bonferroni correction ( p < 6.35 × 10 −5 ). Elevated plasma MANBA (odds ratio [OR] = 1.29, 95% confidence interval [CI] 1.20–1.40, p = 1.22 × 10 −10 ) and CSF TNFSF15 (OR = 6.37, 95% CI 2.94–13.83, p = 2.79 × 10 −6 ) were associated with higher PBC risk, whereas elevated plasma FCRL3 (OR = 0.79, 95% CI 0.73–0.86, p = 2.12 × 10 −8 ) was associated with lower risk. Bayesian colocalization analysis indicated that these protein loci and PBC share the same underlying causal variants.
Conclusion
Elevated plasma MANBA and CSF TNFSF15 levels were linked to increased PBC risk, while higher plasma FCRL3 was protective. Our findings nominate MANBA and TNFSF15 as potential therapeutic targets, while FCRL3 may serve as a protective biomarker for PBC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, ChangChun, Jilin, China.
- China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, Changchun, China.
- Department of Neurology, The First Hospital of Jilin University, ChangChun, Jilin, China.
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Radiology, The First Hospital of Jilin University, Chang Chun, Jilin, China.
- Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR, China.
ORCID-Profile: Guan Huei Lee, Guoyue Lv
Förderung
- Natural Science Foundation of China
- Natural Science Foundation of Jilin Province
- Financial Department of Jilin Province
- National Key Research and Development Program of China
- department of Science and Technology of Jilin Province
Zitieren
APA
Xi, J., Wang, S., Chen, J., Law, J. C. S., Wang, J., Lee, G. H., Fan, Z., Lv, G., & Chen, Y. (2026). Exploration and discovery of treatment targets for primary biliary cholangitis based on plasma and cerebrospinal fluid proteomics: A multicenter mendelian randomization study. PLOS One. https://doi.org/10.1371/journal.pone.0340166
Vancouver
Xi J, Wang S, Chen J, Law JCS, Wang J, Lee GH, et al. Exploration and discovery of treatment targets for primary biliary cholangitis based on plasma and cerebrospinal fluid proteomics: A multicenter mendelian randomization study. PLOS One. 2026. doi:10.1371/journal.pone.0340166
BibTeX
@article{Xi2026,
author = {Xi, Jianxin and Wang, Shengnan and Chen, Jie and Law, Jason Chi Shing and Wang, Jianglong and Lee, Guan Huei and Fan, Zhongqi and Lv, Guoyue and Chen, Yuguo},
title = {Exploration and discovery of treatment targets for primary biliary cholangitis based on plasma and cerebrospinal fluid proteomics: A multicenter mendelian randomization study},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0340166}
}
EUVIMED